Comprehensive medication guide to Spravato including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10–$50 copay per session for most insured patients; Medicare Part B covers 80% of approved costs after the annual deductible. Eligible commercially insured patients pay as little as $10/session with the Spravato withMe Savings Program.
Estimated Cash Pricing
$600–$1,200 per treatment session without insurance (56 mg or 84 mg dose); first month of induction treatment can cost $8,200 or more out of pocket. No retail pharmacy discount programs (GoodRx, etc.) apply.
Medfinder Findability Score
35/100
Summarize with AI
On this page
Spravato (esketamine) is a prescription nasal spray manufactured by Janssen Pharmaceuticals (Johnson & Johnson) and FDA-approved for treatment-resistant depression (TRD) in adults. It was first approved on March 5, 2019, and as of January 2025, became the first and only FDA-approved monotherapy for TRD.
Unlike traditional oral antidepressants that target serotonin or norepinephrine, Spravato works through a completely different mechanism — blocking NMDA receptors in the glutamate pathway. This allows it to produce antidepressant effects within 24 hours of the first dose, far faster than standard antidepressants.
Spravato is approved for: (1) TRD in adults as monotherapy or with an oral antidepressant, for patients who failed at least 2 oral antidepressants; and (2) depressive symptoms in adults with MDD with acute suicidal ideation or behavior, in conjunction with an oral antidepressant. To date, more than 140,000 patients worldwide have received Spravato treatment.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Spravato is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It works by blocking NMDA receptors — channels on brain cells that the excitatory neurotransmitter glutamate normally activates. By blocking these receptors, esketamine triggers downstream molecular cascades that are believed to promote the rapid formation of new synaptic connections (synaptogenesis) in mood-regulating brain regions.
Esketamine is the S-enantiomer of ketamine — a more potent and selective form of the molecule. This rapid synaptic reconnection is thought to underlie the unusually fast antidepressant onset: clinical improvements can begin within 24 hours of the first dose, compared to the 4–8 weeks typically needed by SSRIs and SNRIs.
The precise antidepressant mechanism remains under active scientific investigation. The FDA's prescribing information notes that "the mechanism by which esketamine exerts its antidepressant effect is unknown" — though NMDA antagonism and glutamatergic synaptogenesis are the leading hypotheses backed by extensive preclinical and clinical evidence.
56 mg — nasal spray (2 devices)
2 devices of 28 mg each; TRD induction and maintenance dose
84 mg — nasal spray (3 devices)
3 devices of 28 mg each; standard TRD and MDD-ASIB dose
28 mg — nasal spray (1 device)
Single device; used for geriatric TRD initiation
Spravato is not on the FDA's official drug shortage list, and Janssen continues to manufacture and distribute it without supply interruptions. However, access is severely restricted by the SPRAVATO REMS (Risk Evaluation and Mitigation Strategy) program, which requires that every dose be administered in a certified healthcare setting under direct supervision. Patients cannot take Spravato home.
Access barriers include: limited certified treatment centers (especially in rural areas), insurance prior authorization requirements (1–4 weeks to process), high out-of-pocket costs ($600–$1,200/session without insurance), and the logistical burden of twice-weekly in-clinic visits during the 4-week induction phase — each requiring 2+ hours of post-dose monitoring and a driver to take the patient home.
While Spravato itself isn't available at retail pharmacies, patients managing TRD often take oral medications that can be hard to find at local pharmacies. medfinder calls local pharmacies to find which ones have your prescriptions in stock — saving you the time and frustration of calling around on your own.
As a Schedule III controlled substance administered under the SPRAVATO REMS program, Spravato can be prescribed by any licensed prescriber with DEA prescribing authority. However, in practice, most insurance plans require prescription by or in consultation with a psychiatrist to approve coverage. The prescribing provider does not need to administer the treatment — patients can be referred to a separate REMS-certified treatment center.
Psychiatrists: Primary prescribers; required by most insurance plans; specialize in TRD diagnosis and management
Psychiatric Nurse Practitioners (NPs): Can prescribe in states with full prescribing authority; some insurers require physician oversight
Physician Assistants (PAs): Can prescribe under physician supervision in applicable states
Primary Care Physicians: Can prescribe in consultation with a psychiatrist; typically refer TRD patients to psychiatric specialists
Telehealth is NOT available for Spravato treatment sessions — every dose must be administered in person at a REMS-certified healthcare facility with at least 2 hours of on-site post-dose monitoring. However, prescribers can conduct initial evaluations and follow-up consultations via telehealth, with a referral to a local certified treatment center for the actual treatment sessions.
Yes. Spravato (esketamine) is a Schedule III controlled substance under the Controlled Substances Act. This means it has accepted medical use but carries a moderate-to-low potential for abuse and dependence. As a Schedule III drug, it can be prescribed with refills up to 5 times in a 6-month period, though the REMS program effectively prevents any home dispensing.
Esketamine's controlled substance status is a primary driver of the SPRAVATO REMS program. The REMS exists specifically because of risks of sedation, dissociation, respiratory depression, and potential for abuse — all consistent with the ketamine class. Spravato must be administered at REMS-certified healthcare facilities only and can never be dispensed for home use, regardless of its Schedule III classification.
Most insurance plans require that Spravato be prescribed by or in consultation with a psychiatrist to satisfy coverage requirements. The controlled substance designation also means esketamine can trigger false-positive methadone results on urine drug screens — confirmatory testing is recommended if a positive immunoassay result is obtained.
Most Spravato side effects are acute — occurring during or shortly after each session and resolving within 1–2 hours:
Dissociation (28% in TRD patients) — feeling detached, floating, or spaced out
Sedation (48–61% of patients)
Dizziness (22% in TRD patients)
Nausea and vomiting
Anxiety during session
Headache
Nasal discomfort (burning, irritation)
Respiratory depression (rare; respiratory arrest reported)
Loss of consciousness (0.3–0.4%)
Severe hypertension (seek emergency care if BP ≥180/120 mmHg)
New or worsening suicidal thoughts (boxed warning, especially in patients <24 years)
Bladder problems (ulcerative or interstitial cystitis with long-term use)
Abuse and dependence (Schedule III controlled substance)
Know what you need? Skip the search.
IV Ketamine
Off-label racemic ketamine infusions; rapid onset; typically self-pay $400–$800/infusion; widely available at ketamine clinics
TMS (Transcranial Magnetic Stimulation)
FDA-cleared non-invasive brain stimulation for MDD; covered by most insurers; 30–36 sessions over 6–8 weeks; no drug-related side effects
Auvelity (dextromethorphan/bupropion)
FDA-approved oral NMDA antagonist for MDD; faster onset than SSRIs; taken at home; ~$900/month cash price
ECT (Electroconvulsive Therapy)
Most effective treatment for severe TRD; covered by most insurers; requires brief anesthesia; some short-term memory side effects
Symbyax (olanzapine/fluoxetine)
FDA-approved for TRD; oral combination atypical antipsychotic + SSRI; taken at home; covered by most insurance
Prefer Spravato? We can find it.
Benzodiazepines (alprazolam, diazepam, lorazepam)
majorIncreased sedation and respiratory depression risk. Use with caution; consider holding on treatment days.
Opioids (oxycodone, hydrocodone, fentanyl, buprenorphine)
majorSignificant additive CNS depression and respiratory depression risk.
MAOIs (phenelzine, tranylcypromine, selegiline)
majorRisk of dangerous blood pressure elevation (hypertensive crisis) when combined with esketamine.
Alcohol
majorSignificant additive CNS depression. Do not consume alcohol on treatment days.
Stimulants (amphetamines, methylphenidate)
moderateAdditive blood pressure elevation. Monitor BP closely when combining.
Rifampin
moderateReduces esketamine plasma levels (AUC/Cmax) by 10–25%, potentially reducing effectiveness.
Ticlopidine
moderateIncreases esketamine plasma levels via CYP2B6 inhibition, potentially increasing side effects.
Nasal corticosteroids/decongestants
minorAdminister at least 1 hour before esketamine to avoid reduced nasal absorption.
Spravato represents a genuine clinical breakthrough for adults with treatment-resistant depression — offering the first truly novel antidepressant mechanism approved in decades, with a rapid onset that can provide meaningful relief within hours rather than weeks. Its 2025 expansion to TRD monotherapy status further broadens its clinical utility for patients who cannot tolerate or refuse oral antidepressants.
However, Spravato's REMS program requirements, limited certified treatment center network, insurance prior authorization hurdles, and high cost create real access barriers for many patients. Proactive navigation — finding a certified center, initiating prior authorization early, and enrolling in the Spravato withMe Savings Program — can significantly reduce these barriers.
For patients managing TRD and all the other medications that come with it, medfinder is here to help. We call pharmacies near you to find which ones have your prescriptions in stock — so you can focus on your mental health without the added burden of medication access challenges.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini